Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > For anybody interested in the CYDY story

<< Previous

Bullboard Posts

Next >>

Comment by qwerty22on Jan 13, 2022 6:24pm

108 Views

Post# 34314924

RE:RE:RE:RE:RE:For anybody interested in the CYDY story

Sometimes marketing is just lies. And sometimes just lying works. Hopefully the investigations resolve all this and patients can be re-assured about participation in their trials or stop wasting their time.

SPCEO1 wrote: If the world were normal, this process would already be well advanced. Instead, somehow CYDY has been able to keep all of its spinning plates spinning on the end of those long wobbily sticks and finding people to buy into their utter nonsense while TH has made many notable scientific and regulatory advances, yet no one believes in them. It is one of the most bizarre things I have ever seen. When the Trogarzo deal was first signed we quickly went searching for potential competitors and found CYDY. With regard to MDR, both companies were at a somewhat similar place in the development process but Trogarzo clearly had the backing of the FDA. Now, many years later, Trogarzo has been on the market for nearly three years, TH has added a phase III ready NASH program and a potentially very exciting cancer program as well. During this same time, CYDY accomplished exactly zero. Yet there is CYDY's market cap at $446 million versus TH's at $278 million.

If anyone can make any sense of this, please help!

jfm1330 wrote: It would be fitting to see CYDY back to where it belongs because it is an empty fraudulent shell, and to finally see Thera rise with clear good clinical results out of solid science and steady development work. I really hope it will happen, first for my personal interest, but also as a good lesson about investment. Like a Hollywood movie where the good one wins at the end.